Compare SPPL & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPPL | SER |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | 13 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 19.4M |
| IPO Year | 2022 | N/A |
| Metric | SPPL | SER |
|---|---|---|
| Price | $1.95 | $1.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 13.9K | ★ 7.6M |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $1.22 |
| 52 Week High | $7.00 | $7.92 |
| Indicator | SPPL | SER |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 48.03 |
| Support Level | $1.50 | $1.55 |
| Resistance Level | $3.54 | $3.16 |
| Average True Range (ATR) | 0.27 | 0.35 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 34.09 | 14.60 |
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.